Johnson & Johnson – Page 3

Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

11 months ago talkbio0Tagged Disease remission, Effectiveness, guselkumab, Inflammatory Bowel Diseases, J&J, Johnson & Johnson, Maintenance, Phase 3 Clinical Trials, Safety, Tremfya, Ulcerative Colitis

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.

AbbVie Emerges as Leading Immunology Company in Doctor Rankings, Surpassing Pfizer and Johnson & Johnson

1 year ago talkbio0Tagged AbbVie, Drug Industry, Immunology, Johnson & Johnson, Market, Performance, Pfizer, Physicians, portfolio, product, reputation

AbbVie, Pfizer, Johnson & Johnson, doctor ranking, immunology companies, pharmaceutical industry, market performance, reputation, product portfolio.

“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”

1 year ago talkbio0Tagged Biological Factors, Continuum, Demyelinating Diseases, IPO, Johnson & Johnson, LPAR1 antagonist, LPAR1 gene, Multiple Sclerosis, Neuroinflammation, PIPE-791, Public Offering, Receptors, Lysophosphatidic Acid

Continuum Biologics, PIPE-791, Johnson & Johnson partnership, Initial Public Offering (IPO), Multiple sclerosis, Demyelinating diseases, Neuroinflammation, LPAR1 antagonist, Lysophosphatidic acid receptor Edg-2 antagonist